These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 33595258)

  • 1. Recombinant Human Thrombomodulin Has Additive Effects in Septic Patients Undergoing Continuous Hemodiafiltration Due to Intestinal Perforation.
    Kono H; Hosomura N; Amemiya H; Kawaida H; Furuya S; Akaike H; Kawaguchi Y; Sudo M; Ichikawa D
    Shock; 2021 Sep; 56(3):374-383. PubMed ID: 33595258
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A retrospective comparative study of recombinant human thrombomodulin and gabexate mesilate in sepsis-induced disseminated intravascular coagulation patients.
    Takazono T; Nakamura S; Imamura Y; Yoshioka S; Miyazaki T; Izumikawa K; Sawai T; Matsuo N; Yanagihara K; Suyama N; Kohno S
    J Infect Chemother; 2014 Aug; 20(8):484-8. PubMed ID: 24855912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yoshimura J; Yamakawa K; Ogura H; Umemura Y; Takahashi H; Morikawa M; Inoue Y; Fujimi S; Tanaka H; Hamasaki T; Shimazu T
    Crit Care; 2015 Mar; 19(1):78. PubMed ID: 25883031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can recombinant human thrombomodulin increase survival among patients with severe septic-induced disseminated intravascular coagulation: a single-centre, open-label, randomised controlled trial.
    Hagiwara A; Tanaka N; Uemura T; Matsuda W; Kimura A
    BMJ Open; 2016 Dec; 6(12):e012850. PubMed ID: 28039291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant Human Thrombomodulin Reduces Mortality and Acute Lung Injury Caused by Septic Peritonitis in Rats.
    Kono H; Hosomura N; Amemiya H; Kawaida H; Furuya S; Shoda K; Akaike H; Kawaguchi Y; Ichikawa D
    Immunohorizons; 2023 Jan; 7(1):159-167. PubMed ID: 36706425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy and safety of antithrombin and recombinant human thrombomodulin combination therapy in patients with severe sepsis and disseminated intravascular coagulation.
    Yasuda N; Goto K; Ohchi Y; Abe T; Koga H; Kitano T
    J Crit Care; 2016 Dec; 36():29-34. PubMed ID: 27546744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effects of recombinant human soluble thrombomodulin in patients with severe sepsis: a historical control study.
    Yamakawa K; Fujimi S; Mohri T; Matsuda H; Nakamori Y; Hirose T; Tasaki O; Ogura H; Kuwagata Y; Hamasaki T; Shimazu T
    Crit Care; 2011; 15(3):R123. PubMed ID: 21569368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant human soluble thrombomodulin and mortality in sepsis-induced disseminated intravascular coagulation. A multicentre retrospective study.
    Hayakawa M; Yamakawa K; Saito S; Uchino S; Kudo D; Iizuka Y; Sanui M; Takimoto K; Mayumi T; Ono K;
    Thromb Haemost; 2016 Jun; 115(6):1157-66. PubMed ID: 26939575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation: a multicenter propensity score analysis.
    Yamakawa K; Ogura H; Fujimi S; Morikawa M; Ogawa Y; Mohri T; Nakamori Y; Inoue Y; Kuwagata Y; Tanaka H; Hamasaki T; Shimazu T
    Intensive Care Med; 2013 Apr; 39(4):644-52. PubMed ID: 23361628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis.
    Ogawa Y; Yamakawa K; Ogura H; Kiguchi T; Mohri T; Nakamori Y; Kuwagata Y; Shimazu T; Hamasaki T; Fujimi S
    J Trauma Acute Care Surg; 2012 May; 72(5):1150-7. PubMed ID: 22673239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Determining the Efficacy of Recombinant Human Thrombomodulin in the Treatment of Sepsis-Induced Disseminated Intravascular Coagulation.
    Kotake K; Hongo T; Tahira A; Niimi N; Haisa I; Kawakami Y
    Biol Pharm Bull; 2021 May; 44(5):605-610. PubMed ID: 33612566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of recombinant thrombomodulin administration on disseminated intravascular coagulation due to severe acute cholangitis (Recover-AC study).
    Ogura T; Eguchi T; Nakahara K; Kanno Y; Omoto S; Itonaga M; Kuroda T; Hakoda A; Ikeoka S; Takagi M; Okada A; Sato J; Morita R; Michikawa Y; Ito K; Koshita S; Takenaka M; Kitano M; Koizumi M; Higuchi K
    J Hepatobiliary Pancreat Sci; 2023 Feb; 30(2):221-228. PubMed ID: 34021720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy of recombinant human soluble thrombomodulin for obstetric disseminated intravascular coagulation: a retrospective study.
    Yoshihara M; Uno K; Tano S; Mayama M; Ukai M; Kondo S; Kokabu T; Kishigami Y; Oguchi H
    Crit Care; 2015 Oct; 19():369. PubMed ID: 26481315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of recombinant human soluble thrombomodulin in patients with sepsis-induced disseminated intravascular coagulation - A meta-analysis.
    Kato H; Hagihara M; Asai N; Umemura T; Hirai J; Mori N; Yamagishi Y; Iwamoto T; Mikamo H
    Thromb Res; 2023 Jun; 226():165-172. PubMed ID: 37182388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human soluble thrombomodulin and mortality in severe pneumonia patients with sepsis-associated disseminated intravascular coagulation: an observational nationwide study.
    Tagami T; Matsui H; Horiguchi H; Fushimi K; Yasunaga H
    J Thromb Haemost; 2015 Jan; 13(1):31-40. PubMed ID: 25393713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of recombinant human soluble thrombomodulin on renal function and mortality in septic disseminated intravascular coagulation patients with acute kidney injury: a retrospective study.
    Akatsuka M; Masuda Y; Tatsumi H; Sonoda T
    J Intensive Care; 2020 Dec; 8(1):94. PubMed ID: 33308326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Human Soluble Thrombomodulin Contributes to a Reduction In-Hospital Mortality of Acute Cholangitis with Disseminated Intravascular Coagulation: A Propensity Score Analyses of a Japanese Nationwide Database.
    Tarasawa K; Fujimori K; Fushimi K
    Tohoku J Exp Med; 2020 Sep; 252(1):53-61. PubMed ID: 32879147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant soluble thrombomodulin for postoperative disseminated intravascular coagulation.
    Hashimoto D; Chikamoto A; Miyanari N; Ohara C; Kuramoto M; Horino K; Ohshima H; Baba H
    J Surg Res; 2015 Aug; 197(2):405-11. PubMed ID: 25972310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients.
    Miyoshi S; Ito R; Katayama H; Dote K; Aibiki M; Hamada H; Okura T; Higaki J
    Drug Des Devel Ther; 2014; 8():1211-9. PubMed ID: 25214765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant human soluble thrombomodulin is associated with attenuation of sepsis-induced renal impairment by inhibition of extracellular histone release.
    Akatsuka M; Masuda Y; Tatsumi H; Yamakage M
    PLoS One; 2020; 15(1):e0228093. PubMed ID: 31971961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.